30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.


Anika Responds to CINGAL's Drug Classification

In late 2015, FDA assigned Anika Therapeutics’ CINGAL® to the Center for Drug Evaluation and Research (CDER) and not the Center for Device and Radiological Health (CDRH) for its premarket review—a decision with which Anika’s leadership says it disagrees. 

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.